Detalles de la búsqueda
1.
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Mol Ther Oncolytics
; 20: 459-469, 2021 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33718594
2.
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
J Immunother Cancer
; 4: 17, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26981247
3.
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.
Oncoimmunology
; 3(10): e958937, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25941579
Resultados
1 -
3
de 3
1
Próxima >
>>